Renewed understanding of the diagnosis and treatment guidelines for juvenile dermatomyositis in China
HE Ting-yan
YANG Jun
Abstract：Juvenile Dermatomyositis(JDM)is a chronic autoimmune disease primarily characterized by skin and muscle inflammation,requiring individualized treatment based on disease severity and major organ involved.For non-severe cases,a combination of conventional-dose glucocorticoids with methotrexate serves as the first-line therapy.Methylprednisolone pulse therapy is indicated for severe cases.Recent studies have progressively confirmed the efficacy of intravenous immunoglobulin(IVIG)in JDM.Biological agents and JAK inhibitors may be selectively used for refractory cases,while CAR-T therapy also holds therapeutic promise for these refractory patients.
Keywords：juvenile dermatomyositisbiological agentsJAK inhibitorsintravenous immunoglobulin
Publication Date：2025-09-06
Online Publishing Date：2025-11-05(First online date of this platform, not the publication date of the document)
Pages：5( 724-728 )